Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
23.98
-0.04 (-0.17%)
Oct 19, 2026, 2:05 PM EDT - Market open
Adaptive Biotechnologies Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Adaptive Biotechnologies stock has a consensus rating of "Strong Buy" and an average price target of $29.81. The average 1-year stock price forecast is 24.31% higher than the current stock price, while the lowest is $21 (-12.43%) and the highest is $35 (+45.95%).
Price Target: $29.81 (+24.31%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Adaptive Biotechnologies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Maintains $27 → $30 | Buy | Maintains | $27 → $30 | +25.10% | Oct 14, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $22 → $27 | Hold | Maintains | $22 → $27 | +12.59% | Oct 13, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $28 → $32 | Buy | Maintains | $28 → $32 | +33.44% | Oct 13, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $25 → $32 | Buy | Maintains | $25 → $32 | +33.44% | Oct 1, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Initiates $35 | Buy | Initiates | $35 | +45.95% | Sep 29, 2026 |
Financial Forecast
Revenue This Year
293.43M
from 276.98M
Increased by 5.94%
Revenue Next Year
359.22M
from 293.43M
Increased by 22.42%
EPS This Year
-0.54
from -0.39
EPS Next Year
-0.18
from -0.54
EPS and Forward PE are based on non-GAAP adjusted numbers.